Acclaim-1 – Page 2 – Genprex

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

January 10, 2022Kalyn Dabbs Acclaim 2 Press Releases

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

Multiple clinical trial sites to be opened under oncology research network collaboration

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

June 23, 2021Kalyn Dabbs Acclaim 2 Press Releases

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

May 5, 2021Kalyn Dabbs Acclaim 2 Press Releases

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Company achieves another milestone relating to its clinical trial strategy

Prev
1
2

Designed and Secured by Barsec

Copyright ©2025 all rights reserved.
Home - Privacy Policy - Terms of Use